Which drug lowers cholesterol better? new study compares alirocumab and inclisiran
NCT ID NCT07615166
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study looks at two medicines, alirocumab and inclisiran, that help lower bad cholesterol (LDL-C) in people with heart disease. Researchers will use real-world data from about 124 patients to see which drug reduces cholesterol more over time. The goal is to understand how these treatments compare in everyday medical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sanofi
Bridgewater, New Jersey, 08807, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your smartwatch may predict a heart attack days before it happens
- Could an arthritis drug shield heart and kidneys in metabolic syndrome?
- Heart drug showdown: which statin spares your blood sugar?
- 3,000 volunteers to reveal hidden heart risks in qatar
- Can extremely low cholesterol save more hearts? new trial aims to find out
- Can lowering cholesterol more aggressively help seniors with heart disease?